Report Highlights

Who Controls This Market — And Who Is Threatening That Control

Lineage Logistics and Americold dominate global temperature-controlled warehousing — together operating approximately 45%–50% of institutionally-owned cold storage capacity in North America and growing their European and Asia Pacific footprints through acquisition. Both have REIT structures that provide capital market access for the asset-intensive growth strategy required to build the scale advantages that cold chain logistics enables: consolidated facilities lower operating cost per pallet through energy efficiency, automation investment, and shared overhead. DHL Supply Chain and Kuehne+Nagel lead the pharmaceutical cold chain segment — leveraging their global air freight and express networks to provide end-to-end temperature-controlled pharmaceutical logistics across regulatory-compliant lanes into 200+ countries. Maersk's cold chain integration — combining ocean reefer container capacity, port cold storage, and inland distribution — is the most complete integrated maritime cold chain offer globally. The competitive threat to all incumbents is vertical integration by pharmaceutical manufacturers themselves: AstraZeneca, Pfizer, and Moderna have all invested in proprietary cold chain capabilities following COVID-19 vaccine distribution challenges — reducing their dependence on third-party logistics providers for their most strategically critical supply chains.

Industry Snapshot

The Cold Chain Logistics market was valued at approximately USD 312.4 billion in 2024 and is projected to reach approximately USD 742.8 billion by 2034, growing at a CAGR of 9.0%–11.2%. The market encompasses temperature-controlled warehousing, refrigerated transport (road, rail, ocean, air), value-added services (repackaging, labelling, kitting), and technology platforms (monitoring, tracking, compliance documentation). The pharmaceutical segment — growing at 12%–15% annually — is outpacing the food segment (7%–9%) due to the surge in biologics manufacturing requiring 2°C–8°C cold chain and the emergence of cell and gene therapies requiring cryogenic −196°C infrastructure that represents the most technically demanding and highest-margin cold chain segment ever commercialised. Food cold chain growth is driven by e-commerce grocery expansion, fresh food trade globalisation, and food safety regulatory enforcement in emerging markets.

The Forces Accelerating Demand Right Now

Biologic drug growth is the pharmaceutical cold chain's structural engine. The FDA approved 23 biologics in 2024, representing 48% of novel drug approvals — the highest proportion ever. Biologics require 2°C–8°C cold chain throughout the distribution chain with zero excursions tolerated; a single temperature deviation can render a USD 10,000–50,000 drug dose unusable. This zero-defect requirement drives investment in IoT temperature monitoring, backup power systems, and GDP-compliant documentation that commands 3–5x the service price of standard refrigerated logistics. Cell and gene therapy logistics represents the extreme end: autologous CAR-T cell therapies require patient-specific cryogenic shipments at −196°C from treatment collection to manufacturing facility and back — shipment failures are irreversible (the patient's own cells cannot be replaced) and medical consequences are potentially fatal, creating service requirements and liability profiles unprecedented in commercial logistics history.

E-commerce grocery is the food cold chain growth driver with the most structural permanence. Online grocery penetration reached 12%–15% of grocery spend in the US and UK in 2024, with last-mile cold chain the primary operational constraint. Traditional cold chain infrastructure — large distribution centres and multi-stop reefer truck routes — was not designed for direct-to-consumer home delivery at the 1–5 item order sizes characteristic of online grocery. Micro-fulfilment centres with automated cold picking, insulated packaging systems (Softbox, Cryopak), and temperature-controlled delivery vehicles are the enabling infrastructure that last-mile grocery cold chain requires — a USD 8–12 billion investment cycle underway through 2028.

What Is Holding This Market Back

Energy cost and sustainability pressure are the cold chain's persistent structural challenges. Cold storage warehouses are among the most energy-intensive commercial real estate assets — consuming 5–10 kWh per square foot annually, approximately 10–15x a standard warehouse. Energy represents 30%–40% of cold chain operating cost, creating acute vulnerability to electricity price volatility and significant carbon footprint that is increasingly scrutinised under Scope 3 supply chain emissions reporting frameworks. Lineage Logistics and Americold have both committed to net-zero operations targets, but the path requires significant capital investment in heat pumps, solar generation, and operational efficiency technologies that compress already-thin warehouse margins during the transition period.

Infrastructure shortage in emerging markets is the growth constraint in Asia Pacific, Africa, and Latin America. India, Southeast Asia, and sub-Saharan Africa have cold chain capacity of approximately 0.3–0.8 cubic metres per capita — compared to 5–8 cubic metres in the US and EU — creating post-harvest food loss rates of 30%–40% in fresh produce and limiting the accessible market for temperature-sensitive pharmaceutical distribution. The investment required to bring emerging market cold chain capacity to global norms is estimated at USD 150–200 billion over the forecast period, representing both a market opportunity and a capital mobilisation challenge.

The Investment Case: Bull, Bear, and What Decides It

The bull case rests on three drivers sustaining simultaneously: biologics continuing their 12%–15% growth trajectory, e-commerce grocery cold chain achieving economic sustainability at scale, and emerging market cold chain investment being mobilised by a combination of development finance, foreign direct investment, and domestic government programmes. Combined probability: 50%–60%. The bear case is e-commerce grocery cold chain failing to achieve positive unit economics at scale — leading grocery platforms to pull back from rapid delivery commitments, reducing last-mile cold chain investment significantly. Leading indicator: profitability trajectory of Amazon Fresh, Instacart, and major European rapid grocery delivery platforms through 2026.

Where the Next USD Billion Is Being Built

The 3–5 year value creation opportunity is cell and gene therapy logistics infrastructure — the cryogenic supply chain for autologous and allogeneic cell therapies that requires purpose-built −196°C shipping containers (liquid nitrogen dewars), GPS and temperature real-time tracking, 24/7 chain-of-custody monitoring, and medical emergency response capabilities for shipment failures. The total addressable market for cell and gene therapy logistics is estimated at USD 4–8 billion by 2030, growing at 35%–45% annually from a current base of approximately USD 600 million. The 5–10 year transformative opportunity is autonomous cold chain — AI-routed, EV-powered refrigerated last-mile delivery networks with real-time temperature management and predictive maintenance that reduce cold chain operating cost by 25%–40% versus current labour-intensive models.

Market at a Glance

Regional Intelligence

North America holds approximately 34% of global cold chain revenue, with the most mature temperature-controlled warehousing infrastructure globally — Lineage Logistics and Americold together operating approximately 3.8 billion cubic feet of temperature-controlled capacity concentrated in major food production and distribution corridors (Midwest, California, Texas). The US pharmaceutical cold chain segment is the world's most sophisticated, driven by the FDA's GDP compliance requirements, the concentration of biotechnology manufacturing in the Northeast and California, and the distribution complexity of reaching 50 states with biologics requiring unbroken cold chain compliance. Europe accounts for approximately 28%, with Germany, the Netherlands, and the UK as the primary markets. The Netherlands — as the EU's largest port and logistics hub through Rotterdam — is a particularly significant pharmaceutical cold chain centre, serving as the entry point for temperature-sensitive drug products distributed across the EU. Asia Pacific is the fastest-growing region at 12%–15% annually, driven by India's cold chain infrastructure investment programme (targeting 70 million tonnes of cold storage capacity by 2030 under the National Cold Chain Policy) and Southeast Asia's food cold chain development driven by export-oriented agriculture and rising urban fresh food demand.

Leading Market Participants

• Lineage Logistics (temperature-controlled warehousing REIT)
• Americold Realty Trust
• DHL Supply Chain (pharmaceutical cold chain)
• Kuehne+Nagel (pharma and food cold chain logistics)
• Maersk (ocean reefer and integrated cold chain)
• XPO Logistics (refrigerated road transport)
• CEVA Logistics
• Nichirei Corporation (Japan cold storage)
• VersaCold Logistics Services (Canada)
• Tippmann Group

Frequently Asked Questions

Q1. Frequently Asked Questions ▼

Q2. What temperature ranges are used in pharmaceutical cold chain logistics? ▼

Pharmaceutical cold chain operates across four primary temperature ranges: controlled room temperature (15°C–25°C) for most oral solid dose pharmaceuticals; refrigerated (2°C–8°C) for conventional biologics, vaccines, and many injectables; frozen (−20°C to −40°C) for some biologics and plasma products; and ultra-cold (−60°C to −80°C) for mRNA vaccines and some biologics requiring cryoprotection. The newest segment is cryogenic (−150°C to −196°C liquid nitrogen) for cell and gene therapies — requiring specialist equipment and handling protocols fundamentally different from conventional pharmaceutical cold chain.

Q3. What is Good Distribution Practice (GDP) and why does it matter for cold chain? ▼

Good Distribution Practice is a regulatory standard governing pharmaceutical product storage and distribution, ensuring that drug quality is maintained throughout the supply chain from manufacturer to patient. GDP compliance requires documented temperature monitoring with calibrated equipment, validated shipping lanes, personnel training, emergency procedures for temperature excursions, and audit trail documentation that can be provided to regulatory authorities. GDP compliance is a mandatory market access requirement for pharmaceutical cold chain operators serving regulated markets — it creates barriers to entry and justifies the 3–5x service price premium that GDP-compliant pharmaceutical logistics commands over standard food cold chain.

Q4. How is IoT technology changing cold chain monitoring? ▼

IoT temperature sensors, GPS trackers, and cloud-connected data loggers are replacing paper-based temperature recording and static data loggers with real-time continuous monitoring that generates alerts for temperature excursions before shipments reach their destination. Companies like Sensitech, Emerson (Cargo Track), and Berlinger Special AG supply pharmaceutical cold chain monitoring systems capable of continuous logging at one-minute intervals with cellular or satellite connectivity for global shipment visibility. The regulatory and quality benefit is immediate excursion detection and response; the commercial benefit is reduced product loss and the data record required for regulatory submission and insurance claims. Real-time monitoring is now mandatory for most pharmaceutical cold chain carriers serving major biopharmaceutical companies.

Q5. What is driving cold chain investment in India and Southeast Asia? ▼

India loses approximately 30% of its fruit and vegetable production to post-harvest spoilage due to inadequate cold chain infrastructure — representing an estimated USD 15–18 billion annual economic loss. The Indian government's Cold Chain Infrastructure Development Scheme, combined with PLI (Production-Linked Incentive) schemes for food processing, is targeting 70 million tonnes of cold storage capacity by 2030 from approximately 37 million tonnes in 2024. Southeast Asia's cold chain investment is driven by the region's growing export-oriented agriculture, rising urban food safety standards, and the rapid e-commerce grocery market growth in Indonesia, Vietnam, Thailand, and the Philippines — markets where fresh food delivery is growing at 25%–35% annually from a low base.

Q6. What is the economics of cell and gene therapy cold chain logistics? ▼

Autologous cell therapy logistics — managing the chain of custody for a patient's own cells from leukapheresis collection through CAR-T manufacturing and reinfusion — requires cryogenic shipping containers (liquid nitrogen dewars at −196°C), GPS and temperature real-time monitoring, dedicated medical couriers with 24/7 emergency response capability, and documentation supporting FDA Biologics License Application traceability requirements. The cost of a single patient shipment (round-trip: patient site to manufacturing to patient site) ranges from USD 15,000–35,000 for domestic US shipments to USD 40,000–80,000 for international shipments. This per-patient cost is embedded in the therapy's USD 400,000–600,000 list price, creating a logistics component that represents 5%–15% of total therapy cost — a fundamentally different economics from conventional pharmaceutical logistics.